Nanotech firm prepares for funding, human tests
26th Sep 2005, 04:06 GMT
Development of a cancer-fighting drug based on nanotech research is no small potatoes for Rockville-based CytImmune, which is close to securing $5 million in venture capital to fund human trials.
Latest news from bizjournals.com Health Care:Pharmaceuticals headlines:
- United BioSource makes 10th buy, looks for more
- Nonprofits starting to invest in drug companies
- Accentia making changes to its business formula, market focus
- GSK terminates agreement for Genaera frog product
- Gladstone and Merck team to bring drugs to market
- Abbott expects to double vascular business sales
- Mayo to shut down drug-testing unit
- MIT, Dana-Farber win major cancer grants
- Service Bancorp chair resigns
- Introgen strikes nanotech deal with M.D. Anderson